CSBR - iShares MSCI Brazil ETF USD Acc

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.14
-0.01 (-0.24%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.15
Open4.14
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.93 - 4.30
52 Week Range2.19 - 4.79
Volume35,567
Avg. Volume37,493
Market Cap45.492M
Beta-0.48
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateNov 27, 2017 - Dec 1, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Champions Oncology Inc’s (NASDAQ:CSBR) CEO Pay Matters To You
    Simply Wall St.18 days ago

    Why Champions Oncology Inc’s (NASDAQ:CSBR) CEO Pay Matters To You

    Leading Champions Oncology Inc (NASDAQ:CSBR) as the CEO, Ronnie Morris took the company to a valuation of $43.73M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2018 By the Numbers : December 19, 2017
    Capital Cube29 days ago

    Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2018 By the Numbers : December 19, 2017

    Categories: Yahoo FinanceGet free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc., Riot Blockchain Inc and Foundation Medicine, ... Read more (Read more...)

  • ACCESSWIRElast month

    Blog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalet’s ARYMO ER Extended-Release Tablets C-II

    Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 18, 2017 / Active-Investors issued a free report on Egalet Corp. (NASDAQ: EGLT ), which is readily accessible ...

  • PR Newswirelast month

    Champions Oncology Reports Record Quarterly Revenue of $5.2 Million

    Quarterly operating profit driven by double-digit revenue growth HACKENSACK, N.J. , Dec. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology ...

  • Was Champions Oncology Inc’s (CSBR) Earnings Growth Better Than Industry?
    Simply Wall St.last month

    Was Champions Oncology Inc’s (CSBR) Earnings Growth Better Than Industry?

    Analyzing Champions Oncology Inc’s (NASDAQ:CSBR) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations,Read More...

  • PR Newswire2 months ago

    Champions Oncology to Announce Second Quarter Financial Results on Thursday, December 7, 2017

    HACKENSACK, N.J., Nov. 28, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2017, on Thursday, December 7, 2017, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 22902, or by accessing the Investor tab of the company's website within 72 hours.

  • ACCESSWIRE2 months ago

    Champions Oncology to Present at 10th Annual Main Event on December 5

    HACKENSACK, NJ / ACCESSWIRE / November 27, 2017 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use ...

  • Champions Oncology Inc (CSBR): Time For A Financial Health Check
    Simply Wall St.2 months ago

    Champions Oncology Inc (CSBR): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like Champions Oncology Inc (NASDAQ:CSBR), with a market cap of USD $41.75M. However, an important fact which most ignore is: howRead More...

  • PR Newswire2 months ago

    Champions Oncology to Participate in the Craig-Hallum Alpha Select Investor Conference

    HACKENSACK, N.J., Nov. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, will be participating in the 8th Annual Craig-Hallum Alpha Select Conference on November 16th. To schedule a meeting, please contact your Craig-Hallum representative, or Hayden IR. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.

  • Champions Oncology Inc (CSBR) And The Healthcare Industry Prospect For 2017
    Simply Wall St.3 months ago

    Champions Oncology Inc (CSBR) And The Healthcare Industry Prospect For 2017

    Champions Oncology Inc (NASDAQ:CSBR), a USD$36.03M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • PR Newswire4 months ago

    Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

    HACKENSACK, N.J., Sept. 26, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government's Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. The project will build and study an ethnically diverse cohort of metastatic prostate patient-derived xenograft (PDX) models.  Fully characterized, ethnically diverse prostate PDX models are under-represented among PDX banks, limiting opportunities for pre-clinical and translational oncology studies.  Not only is the incidence of prostate cancer higher in African American men than other ethnic groups, the mortality rates from prostate cancer for African American men are higher.  A primary goal of this project is to create new tools to better understand the ethnic health disparity in prostate cancer.

  • Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
    Capital Cube4 months ago

    Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc. and Foundation Medicine, Inc. (AVIR-US, CRL-US, ... Read more (Read more...)

  • PR Newswire4 months ago

    Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies

    HACKENSACK, N.J. , Sept. 18, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the ...

  • PR Newswire4 months ago

    Champions Oncology Reports Record Quarterly Revenue of $5 Million

    37.1% year-over-year revenue increase HACKENSACK, N.J. , Sept. 14, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services ...

  • PR Newswire4 months ago

    Champions Oncology to Announce First Quarter Financial Results on Thursday, September 14, 2017

    HACKENSACK, N.J., Sept. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2017, on Thursday, September 14, 2017, after market close. The company will host a conference call to discuss the results that day at 5:00 p.m. EST (2:00 p.m. PST). A replay of the call will be available on the Investor tab of the company's website within 72 hours.

  • PR Newswire5 months ago

    Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

    HACKENSACK, N.J., Aug. 21, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models.

  • PR Newswire5 months ago

    Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models

    HACKENSACK, N.J., Aug. 18, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a collaboration with The Addario Lung Cancer Medical Institute "ALCMI" to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement.  These models will further expand Champions' TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers.  Champions' global infrastructure will be leveraged to support this multi-year program. As a patient-driven initiative, ALCMI is leading an international study, with Champions Oncology contributing its extensive experience and global infrastructure, to support the establishment of patient derived xenograft models from patients with a ROS1 fusion.

  • The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer
    PR Newswire5 months ago

    The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer

    SAN CARLOS, Calif. and HACKENSACK, N.J., Aug. 15, 2017 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (CSBR), and the ROS1ders (voiced as "ross wonders") announce a preclinical study that will develop new models of cancers expressing a ROS1 gene rearrangement. This study is part of The Global ROS1 Research Initiative, which focuses on improving outcomes for this uncommon yet clinically important oncogene-driven cancer. The ROS1ders are a group of patients and caregivers dealing with ROS1 positive cancers, regardless of where the cancer originated.

  • ACCESSWIRE5 months ago

    Corporate News Blog - Theravance Biopharma’s Velusetrag Successful in Mid-Stage Gastroparesis Study

    Research Desk Line-up: Champions Oncology Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017
    Capital Cube6 months ago

    Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended April 30, 2017. Highlights Summary numbers: Revenues of USD 3.72 million, Net Earnings of USD -2.42 million. Gross margins widened from 17.45% to 30.89% compared to the same period last year, operating (EBITDA) margins now -63.12% from -88.37%. Change in operating ... Read more (Read more...)

  • PR Newswire6 months ago

    Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017

    HACKENSACK, N.J. , July 27, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use ...

  • PR Newswire6 months ago

    Champions Oncology Schedules Fourth Quarter and Fiscal Year 2017 Earnings Call

    HACKENSACK, N.J., July 17, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2017, on Thursday, July 27, 2017, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available on the Investor tab of the company's website within 72 hours.

  • Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017
    Capital Cube10 months ago

    Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017

    Categories: Yahoo Finance Get free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended January 31, 2017. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc. and Foundation Medicine, Inc. (AVIR-US, CRL-US, ... Read more (Read more...)

  • PR Newswire10 months ago

    Champions Oncology Reports 40% Revenue Growth

    HACKENSACK, N.J., March 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use ...

  • PR Newswire10 months ago

    Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland

    HACKENSACK, N.J., March 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced plans for opening a new lab facility in Rockville, Maryland during the second quarter of its 2018 fiscal year. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.